Novartis has entered into a definitive agreement to acquire Excellergy, a privately held biotechnology company, for up to $2 billion. The deal includes an upfront payment and additional contingent milestone payments, subject to customary closing conditions.
The acquisition is centered on Excellergy's pipeline of novel trifunctional effector cell response inhibitors, a new class of investigational cancer immunotherapies. These therapies are designed to enhance the body's immune response against tumors by simultaneously engaging multiple immune cell pathways.
Novartis stated the acquisition aims to bolster its oncology portfolio with potentially first-in-class treatments. The transaction is expected to close in the second half of 2026, pending regulatory approvals.
Financial analysts note the deal highlights continued strong investment in the oncology sector, particularly for innovative immunotherapy platforms. The specific financial terms, including the split between upfront and milestone payments, were not publicly disclosed in the initial announcement.
